Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

Bard, Frédérique, Cannon, Catherine, Barbour, Robin, Burke, Rae-Lyn, Games, Dora, Grajeda, Henry, Guido, Teresa, Hu, Kang +15 more·2000·Nature Medicine
DOI 10.1038/78682

Cited by (1,003)

Items 401–500 of 1,003

  1. Neurobiology of microglial action in CNS injuries: Receptor-mediated signaling mechanisms and functional roles
    Xiaoming Hu, Anthony K. F. Liou, Rehana K. Leak, Mingyue Xu, Chengrui An, Jun Suenaga, Yejie Shi, Yanqin Gao, Ping Zheng, Jun Chen · 2014 · Progress in Neurobiology
  2. Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders
    Elvira Valera, Brian J. Spencer, Eliezer Masliah · 2015 · Neurotherapeutics
  3. Core biological marker candidates of Alzheimer?s disease ? perspectives for diagnosis, prediction of outcome and reflection of biological activity
    Harald Juergen Hampel, Alex J. Mitchell, Kaj Blennow, Richard Frank, Sylvia Brettschneider, Lindsey Jean Ross Weller, H.-J. M�ller · 2004 · Journal of Neural Transmission
  4. Alzheimer’s disease as oligomeropathy
    Ono, Kenjiro · 2018 · Neurochemistry International
  5. A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice
    Varsha Shukla, Yali Zheng, Santosh Kumar Mishra, Niranjana D. Amin, Joseph P. Steiner, Philip G. Grant, Sashi Kesavapany, Harish C. Pant · 2012 · The FASEB Journal
  6. Inflammation, Apoptosis, and Alzheimer's Disease
    Maria E. Bamberger, Gary E. Landreth · 2002 · The Neuroscientist
  7. Behavioral Assessment of Alzheimer's Transgenic Mice Following Long-Term A β Vaccination: Task Specificity and Correlations between A β Deposition and Spatial Memory
    Gary W. Arendash, Marcia N. Gordon, David M. Diamond, Leigh Ann Austin, Jaime M. Hatcher-Martin, Paul T. Jantzen, Giovanni DiCarlo, Donna M. Wilcock, David Morgan · 2001 · DNA and Cell Biology
  8. Tau‐targeted treatment strategies in Alzheimer's disease
    Jürgen Götz, Arne Ittner, Lars Matthias Ittner · 2011 · British Journal of Pharmacology
  9. Structure-based drug design identifies polythiophenes as antiprion compounds
    U. Herrmann, Anne K. Schütz, Hamid Shirani, Danzhi Huang A, Dino Vitali Saban, Mario Nuvolone, Bei Li, Boris Ballmer, Andreas Åslund, Jeffrey J. Mason et al. · 2015 · Science Translational Medicine
  10. Does my mouse have Alzheimer's disease?
    Jean‐Cosme Dodart, Chantal Mathis, Kelly R. Bales, Steven M. Paul · 2002 · Genes Brain & Behavior
  11. FcγRIIb mediates amyloid-β neurotoxicity and memory impairment in Alzheimer’s disease
    Kam, Tae-In, Song, Sungmin, Gwon, Youngdae, Park, Hyejin, Yan, Ji-Jing, Im, Isak, Choi, Ji-Woo, Choi, Tae-Yong, Kim, Jeongyeon, Song, Dong-Keun et al. · 2013 · Journal of Clinical Investigation
  12. Anti-ApoE Antibody Given after Plaque Onset Decreases Aβ Accumulation and Improves Brain Function in a Mouse Model of Aβ Amyloidosis
    Liao, Fan, Hori, Yukiko, Hudry, Eloise, Bauer, Adam Q., Jiang, Hong, Mahan, Thomas E., Lefton, Katheryn B., Zhang, Tony J., Dearborn, Joshua T., Kim, Jungsu et al. · 2014 · The Journal of Neuroscience
  13. Intracranial Adeno-Associated Virus-Mediated Delivery of Anti-Pan Amyloid β, Amyloid β40, and Amyloid β42 Single-Chain Variable Fragments Attenuates Plaque Pathology in Amyloid Precursor Protein Mice
    Yona Levites, Karen R. Jansen, Lisa A. Smithson, Rachel S. Dakin, Vallie M. Holloway, Pritam Das, Todd Eliot Golde · 2006 · Journal of Neuroscience
  14. Norepinephrine Promotes Microglia to Uptake and Degrade Amyloid β Peptide through Upregulation of Mouse Formyl Peptide Receptor 2 and Induction of Insulin-Degrading Enzyme
    Yan Kong, Lingfei Ruan, Lihua Qian, Xiaolei Liu, Yingying Le · 2010 · Journal of Neuroscience
  15. Antibodies against β‐amyloid reduce aβ oligomers, glycogen synthase kinase‐3β activation and τ phosphorylation in vivo and in vitro
    Ma, Qiu‐Lan, Lim, Giselle P., Harris‐White, Marni E., Yang, Fusheng, Ambegaokar, Surendra S., Ubeda, Oliver J., Glabe, Charles G., Teter, Bruce, Frautschy, Sally A., Cole, Greg M. · 2006 · Journal of Neuroscience Research
  16. GM1-Modified Lipoprotein-like Nanoparticle: Multifunctional Nanoplatform for the Combination Therapy of Alzheimer’s Disease
    Huang, Meng, Hu, Meng, Song, Qingxiang, Song, Huahua, Huang, Jialin, Gu, Xiao, Wang, Xiaolin, Chen, Jun, Kang, Ting, Feng, Xingye et al. · 2015 · ACS Nano
  17. Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer’s Disease
    Md. Sahab Uddin, Md. Tanvir Kabir, Md. Sohanur Rahman, Tapan Behl, Philippe Jeandet, Ghulam Md Ashraf, Agnieszka Najda, May Nasser Bin-Jumah, Hesham Rushdey El-Seedi, Mohamed M. Abdel‐Daim · 2020 · International Journal of Molecular Sciences
  18. β-sheet breaker peptide prevents Aβ-induced spatial memory impairments with partial reduction of amyloid deposits
    Marcelo A. Chacón, María Inés Barría, Claudio A. Soto, Nibaldo C. Inestrosa · 2004 · Molecular Psychiatry
  19. Treatment Strategies Targeting Amyloid -Protein
    Dale Schenk, G.S. Basi, Menelas N. Pangalos · 2012 · Cold Spring Harbor Perspectives in Medicine
  20. Immunotherapy for Alzheimer‘s Disease: From Anti-β-Amyloid to Tau-Based Immunization Strategies
    Francesco Panza, Vincenza Frisardi, Vincenzo Solfrizzi, Bruno Pietro Imbimbo, Giancarlo Logroscino, Andrea Santamato, Antonio Greco, Davide Seripa, Alberto Pilotto · 2012 · Immunotherapy
  21. and Alzheimer's disease
    Jorge D. Brioni, Tim A. Esbenshade, Tiffany Runyan Garrison, Scott R. Bitner, Marlon Cowart · 2010
  22. Curcumin restores innate immune Alzheimer's disease risk gene expression to ameliorate Alzheimer pathogenesis
    Bruce Teter, Takashi Morihara, Giselle P. Lim, T. Chu, Mychica R. Jones, Xiaohong Zuo, R.M. Paul, Sally Ann Frautschy, Greg M. Cole · 2019 · Neurobiology of Disease
  23. Phagocytosis of Amyloid-β and Inflammation: Two Faces of Innate Immunity in Alzheimer's Disease
    Milan Fiala, David H. Cribbs, Mark J. Rosenthal, George W. Bernard · 2007 · Journal of Alzheimer s Disease
  24. Single-domain antibodies recognize selectively small oligomeric forms of amyloid β, prevent Aβ-induced neurotoxicity and inhibit fibril formation
    Pierre J. Lafaye, Ikbel Achour, Patrick England, Charles J. Duyckaerts, François Rougeon · 2008 · Molecular Immunology
  25. Intracerebroventricular amyloid-β antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice
    Thakker, Deepak R., Weatherspoon, Marcy R., Harrison, Jonathan, Keene, Thomas E., Lane, Deanna S., Kaemmerer, William F., Stewart, Gregory R., Shafer, Lisa L. · 2009 · Proceedings of the National Academy of Sciences
  26. Peripheral T cells overexpress MIP-1α to enhance its transendothelial migration in Alzheimer's disease
    Shumei Man, Yiran Ma, De‐Shu Shang, Wei‐Dong Zhao, Bo Li, Dawen Guo, Wen‐Gang Fang, Li Zhu, Yuhua Chen · 2006 · Neurobiology of Aging
  27. Circulating Biomarkers of Cognitive Decline and Dementia
    Solfrizzi, Vincenzo, D'Introno, Alessia, Colacicco, Anna Maria, Capurso, Cristiano, Todarello, Orlando, Pellicani, Vincenza, Capurso, Sabrina A, Pietrarossa, Giuseppe, Santamato, Vito, Capurso, Antonio et al. · 2006 · Clinica Chimica Acta
  28. Naturally Occurring Autoantibodies against β-Amyloid: Investigating Their Role in Transgenic Animal andIn VitroModels of Alzheimer's Disease
    Richard C. Dodel, Karthikeyan Balakrishnan, Kathy Keyvani, Oliver Deuster, Frauke Neff, Luminita‐Cornelia Andrei‐Selmer, Stephan Röskam, Carsten Stüer, Yousef Al‐Abed, Carmen Noelker et al. · 2011 · Journal of Neuroscience
  29. Monoclonal Antibodies against Aβ42 Fibrils Distinguish Multiple Aggregation State Polymorphisms in Vitro and in Alzheimer Disease Brain
    Asa Hatami, Ricardo Albay, Sanaz Monjazeb, Saskia C. F. Milton, Charles G. Glabe · 2014 · Journal of Biological Chemistry
  30. Novel targets for Alzheimer's disease treatment
    J. Grill, J. Cummings · 2010 · Expert Review of Neurotherapeutics
  31. CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid β‐peptide
    Townsend, Kirk P., Town, Terrence, Mori, Takashi, Lue, Lih‐Fen, Shytle, Doug, Sanberg, Paul R., Morgan, David, Fernandez, Francisco, Flavell, Richard A., Tan, Jun · 2005 · European Journal of Immunology
  32. The role of innate immunity in Alzheimer's disease
    Hannah E. Ennerfelt, John R. Lukens · 2020 · Immunological Reviews
  33. Therapeutic Strategies for Alzheimer’s Disease
    Donna M. Barten, Charles F. Albright · 2008 · Molecular Neurobiology
  34. β‐Secretase‐1 elevation in transgenic mouse models of Alzheimer’s disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development
    Xue‐Mei Zhang, Yan Cai, Kun Xiong, Huaibin Cai, Xuegang Luo, Jiachun Feng, Richard W. Clough, Robert G. Struble, Peter R. Patrylo, Xiao‐Xin Yan · 2009 · European Journal of Neuroscience
  35. Role of Endosomes and Lysosomes in Human Disease
    Frederick R. Maxfield · 2014 · Cold Spring Harbor Perspectives in Biology
  36. Internalized Antibodies to the Aβ Domain of APP Reduce Neuronal Aβ and Protect against Synaptic Alterations
    Tampellini, Davide, Magrané, Jordi, Takahashi, Reisuke H., Li, Feng, Lin, Michael T., Almeida, Cláudia G., Gouras, Gunnar K. · 2007 · Journal of Biological Chemistry
  37. Robust amyloid clearance in a mouse model of Alzheimer’s disease provides novel insights into the mechanism of amyloid-β immunotherapy
    Wang, Allan, Das, Pritam, Switzer, Robert C., Golde, Todd E., Jankowsky, Joanna L. · 2011 · The Journal of Neuroscience
  38. Impact of amyloid imaging on drug development in Alzheimer's disease
    Chester A. Mathis, Brian J. Lopresti, William Edward Klunk · 2007 · Nuclear Medicine and Biology
  39. Alzheimer's disease: β‐Amyloid protein and tau
    Maho Morishima‐Kawashima, Yasuo Ihara · 2002 · Journal of Neuroscience Research
  40. Hippocampal expression of murine TNFα results in attenuation of amyloid deposition in vivo
    Chakrabarty, Paramita, Herring, Amanda, Ceballos-Diaz, Carolina, Das, Pritam, Golde, Todd E · 2011 · Molecular Neurodegeneration
  41. Disease modifying therapy for AD?<sup>1</sup>
    Golde, Todd E. · 2006 · Journal of Neurochemistry
  42. Immunotherapy Targeting Pathological Tau Protein in Alzheimer's Disease and Related Tauopathies
    Sigurdsson, Einar M. · 2008 · Journal of Alzheimer's Disease
  43. Aβ Immunotherapy: Intracerebral Sequestration of Aβ by an Anti-Aβ Monoclonal Antibody 266 with High Affinity to Soluble Aβ
    Yamada, Kaoru, Yabuki, Chiori, Seubert, Peter, Schenk, Dale, Hori, Yukiko, Ohtsuki, Sumio, Terasaki, Tetsuya, Hashimoto, Tadafumi, Iwatsubo, Takeshi · 2009 · The Journal of Neuroscience
  44. Pharmacokinetics and Brain Uptake of a Genetically Engineered Bifunctional Fusion Antibody Targeting the Mouse Transferrin Receptor
    Rubén J. Boado, Qing-Hui Zhou, Jeff Zhiqiang Lu, Eric Ka‐Wai Hui, William M. Pardridge · 2009 · Molecular Pharmaceutics
  45. Pharmacotherapy for Alzheimer's disease: progress and prospects
    Alan M. Palmer · 2002 · Trends in Pharmacological Sciences
  46. Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice
    Roberto Furlan · 2003 · Brain
  47. Microglial activatory (immunoreceptor tyrosine‐based activation motif)‐ and inhibitory (immunoreceptor tyrosine‐based inhibition motif)‐signaling receptors for recognition of the neuronal glycocalyx
    Bettina Linnartz‐Gerlach, Harald Neumann · 2012 · Glia
  48. Dual-Sensitive Nanomicelles Enhancing Systemic Delivery of Therapeutically Active Antibodies Specifically into the Brain
    Jinbing Xie, Daniel Gonzalez‐Carter, Theofilus A. Tockary, Noriko Nakamura, Yonger Xue, Makoto Nakakido, Hiroki Akiba, Anjaneyulu Dirisala, Xueying Liu, Kazuko Toh et al. · 2020 · ACS Nano
  49. Current Understanding of Natural Antibodies and Exploring the Possibilities of Modulation Using Veterinary Models. A Review
    G. IJsbrand Reyneveld, Huub F. J. Savelkoul, H.K. Parmentier · 2020 · Frontiers in Immunology
  50. Amyloid β Interaction with Receptor for Advanced Glycation End Products Up-Regulates Brain Endothelial CCR5 Expression and Promotes T Cells Crossing the Blood-Brain Barrier
    Man Li, De‐Shu Shang, Wei‐Dong Zhao, Tian Xiang Li, Bo Li, Wen‐Gang Fang, Li Zhu, Shumei Man, Yuhua Chen · 2009 · The Journal of Immunology
  51. Alzheimer disease macrophages shuttle amyloid-beta from neurons to vessels, contributing to amyloid angiopathy
    Justin Zaghi, Benjamin Goldenson, Mohammed Inayathullah, A. S. Lossinsky, Ava Masoumi, Hripsime Avagyan, Michelle Mahanian, Michael J. Bernas, Martin E. Weinand, Mark J. Rosenthal et al. · 2009 · Acta Neuropathologica
  52. Agile delivery of protein therapeutics to CNS
    Xiang Yi, Devika Soundara Manickam, Anna M. Brynskikh, Alexander V. Kabanov · 2014 · Journal of Controlled Release
  53. Selection of RNA Aptamers to the Alzheimer's Disease Amyloid Peptide
    Francisco Ylera, Rudi Lurz, Volker A. Erdmann, Jens Peter Fürste · 2002 · Biochemical and Biophysical Research Communications
  54. Microglia Lacking E Prostanoid Receptor Subtype 2 Have Enhanced Aβ Phagocytosis yet Lack Aβ-Activated Neurotoxicity
    Feng‐Shiun Shie, RICHARD M. BREYER, Thomas Jude Montine · 2005 · American Journal Of Pathology
  55. Microglia
    Julia Kofler, Clayton A. Wiley · 2010 · Toxicologic Pathology
  56. Differential neuroimmune markers to the onset of Alzheimer's disease neurodegeneration and dementia: Autoantibodies to Aβ(25–35) oligomers, S100b and neurotransmitters
    Грудень Марина Алексеевна, Tatyana B. Davidova, Mantas Mališauskas, Robert D. E. Sewell, Nina I. Voskresenskaya, K. Wilhelm, E. I. Elistratova, Vladimir V. Sherstnev, Ludmilla A. Morozova‐Roche · 2007 · Journal of Neuroimmunology
  57. Insights into the mechanisms of action of anti‐Aβ antibodies in Alzheimer's disease mouse models
    Levites, Yona, Smithson, Lisa A., Price, Robert W., Dakin, Rachel S., Yuan, Bin, Sierks, Michael R., Kim, Jungsu, McGowan, Eileen, Kim Reed, Dana, Rosenberry, Terrone L. et al. · 2006 · The FASEB Journal
  58. A Review of the Brain-Gut-Microbiome Axis and the Potential Role of Microbiota in Alzheimer’s Disease
    Sun, Miao, Ma, Kai, Wen, Jie, Wang, Guangxian, Zhang, Changliang, Li, Qi, Bao, Xiaofeng, Wang, Hui · 2020 · Journal of Alzheimer’s Disease
  59. Peripherally Administered Human Umbilical Cord Blood Cells Reduce Parenchymal and Vascular β -Amyloid Deposits in Alzheimer Mice
    William V. Nikolic, Huayan Hou, Terrence Town, Yuyan Zhu, Brian N. Giunta, Cyndy Davis Sanberg, Jin Zeng, Deyan Luo, Jared C. Ehrhart, Takashi Mori et al. · 2008 · Stem Cells and Development
  60. Neurological disorders and therapeutics targeted to surmount the blood–brain barrier
    Jagat R. Kanwar, Sriramoju, Kanwar · 2012 · International Journal of Nanomedicine
  61. Amyloid β -Protein Assembly as a Therapeutic Target of Alzheimers Disease
    Ghiam Yamin, Kenjiro Ono, Mohammed Inayathullah, David B. Teplow · 2008 · Current Pharmaceutical Design
  62. Cerebral amyloid angiopathy: Pathogenesis and effects on the ageing and Alzheimer brain
    Roy O. Weller, James A. R. Nicoll · 2003 · Neurological Research
  63. Immunogenicity, Efficacy, Safety, and Mechanism of Action of Epitope Vaccine (Lu AF20513) for Alzheimer's Disease: Prelude to a Clinical Trial
    Davtyan, Hayk, Ghochikyan, Anahit, Petrushina, Irina, Hovakimyan, Armine, Davtyan, Arpine, Poghosyan, Anna, Marleau, Annette M., Movsesyan, Nina, Kiyatkin, Anatoly, Rasool, Suhail et al. · 2013 · The Journal of Neuroscience
  64. Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice
    Ksenia V. Kastanenka, Thierry Bussière, Naomi B. Shakerdge, Fang Qian, Paul H. Weinreb, Ken Rhodes, Brian J. Bacskai · 2016 · Journal of Neuroscience
  65. Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated α-synuclein
    Jinghua Jin, Feng‐Shiun Shie, Jun Liu, Yan Wang, Jeanne Davis, Aimee M. Schantz, Kathleen S. Montine, Thomas Jude Montine, Jing Zhang · 2007 · Journal of Neuroinflammation
  66. Aβ-globulomers are formed independently of the fibril pathway
    Gerald P. Gellermann, Helga Byrnes, Andreas Striebinger, Kathrin Ullrich, Reinhold Mueller, Heinz Hillen, Stefan Barghorn · 2008 · Neurobiology of Disease
  67. Inhibition of Alzheimer's disease β‐amyloid aggregation, neurotoxicity, and in vivo deposition by nitrophenols: implications for Alzheimer's therapy
    Fernanda G. De Felice, Jean‐Christophe Houzel, José Garcia-Abreu, Paulo Roberto Louzada, Rosenilde Carvalho de Holanda Afonso, M. N. L. Meirelles, Roberto Lent, Vivaldo Moura Neto, Sergio Teixeira Ferreira · 2001 · The FASEB Journal
  68. Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer’s disease
    Lassmann, Hans · 2011 · Journal of Neural Transmission
  69. Distinct Therapeutic Mechanisms of Tau Antibodies
    Funk, Kristen E., Mirbaha, Hilda, Jiang, Hong, Holtzman, David M., Diamond, Marc I. · 2015 · Journal of Biological Chemistry
  70. Aβ peptide immunization restores blood‐brain barrier integrity in Alzheimer disease
    Dickstein, Dara L., Biron, Kaan E., Ujiie, Maki, Pfeifer, Cheryl G., Jeffries, Andrew R., Jefferies, Wilfred A. · 2006 · The FASEB Journal
  71. Central nervous system myeloid cells as drug targets: current status and translational challenges
    Knut P. H. Biber, Thomas Möller, Erik Boddeke, Marco Prinz · 2015 · Nature Reviews Drug Discovery
  72. Role of the Immune System in the Pathogenesis, Prevention and Treatment of Alzheimer??s Disease
    Blasko, Imrich, Grubeck-Loebenstein, Beatrix · 2003 · Drugs &amp; Aging
  73. ADDLs and the signaling web that leads to Alzheimer’s disease
    Grant A. Krafft, William L. Klein · 2010 · Neuropharmacology
  74. Loss of NPC1 enhances phagocytic uptake and impairs lipid trafficking in microglia
    Alessio Vittorio Colombo, Lina Dinkel, Stephan A. Müller, Laura Sebastián Monasor, Martina Schifferer, Ludovico Cantuti‐Castelvetri, Jasmin König, Lea Vidatic, Tatiana Brémovà-Ertl, Andrew P. Lieberman et al. · 2021 · Nature Communications
  75. Neuronal Structure is Altered by Amyloid Plaques
    Tara L. Spires‐Jones, Bradley T. Hyman · 2004 · Reviews in the Neurosciences
  76. Uptake and pathogenic effects of amyloid beta peptide 1–42 are enhanced by integrin antagonists and blocked by NMDA receptor antagonists
    Xiaoning Bi, Christine M. Gall, Jun Zhou, GARY S. LYNCH · 2002 · Neuroscience
  77. Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease
    Richard C. Dodel, Frauke Neff, Carmen Noelker, Refik Pul, Yansheng Du, Michael Bacher, Wolfgang H. Oertel · 2010 · Drugs
  78. Cannabinoids and the Brain
    Attila Köfalvi · 2007 · Springer eBooks
  79. Gene expression profiling of scrapie-infected brain tissue
    Riemer, Constanze, Neidhold, Sabine, Burwinkel, Michael, Schwarz, Anja, Schultz, Julia, Krätzschmar, Jörn, Mönning, Ursula, Baier, Michael · 2004 · Biochemical and Biophysical Research Communications
  80. Towards Disease-Modifying Treatment of Alzheimers Disease: Drugs Targeting β -Amyloid
    Vincenza Frisardi, Vincenzo Solfrizzi, Bruno Pietro Imbimbo, Cristiano A. Capurso, Alessia D’Introno, Anna Maria Colacicco, Gianluigi Vendemiale, Davide Seripa, Alberto Pilotto, Cristiano A. Capurso et al. · 2010 · Current Alzheimer Research
  81. Subcutaneous Nogo Receptor Removes Brain Amyloid-β and Improves Spatial Memory in Alzheimer's Transgenic Mice
    James Hugh Park, Gabriel A. Widi, David A. Gimbel, Noam Y. Harel, Daniel H. S. Lee, Stephen M. Strittmatter · 2006 · Journal of Neuroscience
  82. Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-β without concomitant T cell responses
    Bryce Chackerian, Marisa Rangel, Zoe N. Hunter, David S. Peabody · 2006 · Vaccine
  83. Molecular basis for passive immunotherapy of Alzheimer's disease
    Anna S. Gardberg, Lezlee T. Dice, Susan Ker-hwa Ou, Rebecca L. Rich, Elizabeth Helmbrecht, Jan Ko, Ronald B. Wetzel, David G. Myszka, Paul H. Patterson, Chris Godfrey Dealwis · 2007 · Proceedings of the National Academy of Sciences
  84. Nitric Oxide‐Releasing Drugs
    Jean‐Luc Burgaud, Ennio Ongini, Piero Del Soldato · 2002 · Annals of the New York Academy of Sciences
  85. M-CSF increases proliferation and phagocytosis while modulating receptor and transcription factor expression in adult human microglia
    Smith, Amy M, Gibbons, Hannah M, Oldfield, Robyn L, Bergin, Peter M, Mee, Edward W, Curtis, Maurice A, Faull, Richard L M, Dragunow, Mike · 2013 · Journal of Neuroinflammation
  86. Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition
    Chakrabarty, Paramita, Tianbai, Li, Herring, Amanda, Ceballos-Diaz, Carolina, Das, Pritam, Golde, Todd E · 2012 · Molecular Neurodegeneration
  87. Review: Therapy for Alzheimer's disease: how effective are current treatments?
    Krista L. Lanctôt, Ryan D. Rajaram, Nathan Herrmann · 2009 · Therapeutic Advances in Neurological Disorders
  88. Stem Cell Therapy for Alzheimer’s Disease: A Review of Recent Clinical Trials
    Jae Myeong Kang, Byeong Kil Yeon, Seong‐Jin Cho, Yoo‐Hun Suh · 2016 · Journal of Alzheimer s Disease
  89. Natural human antibodies to amyloid beta peptide
    Paul Szabo, Norman R. Relkin, Marc E. Weksler · 2008 · Autoimmunity Reviews
  90. Anti-Amyloid-β Immunotherapy in Alzheimer's Disease: Relevance of Transgenic Mouse Studies to Clinical Trials
    Donna M. Wilcock, Carol A. Colton · 2008 · Journal of Alzheimer s Disease
  91. The endocannabinoid pathway in Huntington's disease: A comparison with other neurodegenerative diseases
    Mauro Maccarrone, Natalia Battista, Diego Centonze · 2007 · Progress in Neurobiology
  92. Systemic and Acquired Immune Responses in Alzheimer's Disease
    Markus Britschgi, Tony Wyss‐Coray · 2007 · International review of neurobiology
  93. Microglial alterations in human Alzheimer's disease following Aβ42 immunization
    E. Zotova, Clive Holmes, David Annandale Johnston, James Neal, James A. R. Nicoll, Delphine Boche · 2010 · Neuropathology and Applied Neurobiology
  94. Autoantibodies to Amyloid β-Peptide (Aβ) are Increased in Alzheimer's Disease Patients and Aβ Antibodies Can Enhance Aβ Neurotoxicity: Implications for Disease Pathogenesis and Vaccine Development
    Avindra Nath, Elizabeth Hall, Marnia Tuzova, Michael Dobbs, Melina Jones, Caroline Anderson, Jerold G. Woodward, Zhihong Guo, Weiming Fu, Richard J. Kryscio et al. · 2003 · NeuroMolecular Medicine
  95. The role and therapeutic potential of monocytic cells in Alzheimer's disease
    Tarja Malm, Milla Koistinaho, Anu Muona, Johanna M. Magga, Jari Koıstınaho · 2010 · Glia
  96. Microglial transplantation increases amyloid‐β clearance in Alzheimer model rats
    Kazuyuki Takata, Yoshihisa Kitamura, Daijiro Yanagisawa, Shigehiro Morikawa, Masahito Morita, Toshiro Inubushi, Daiju Tsuchiya, Saori Chishiro, Mana Saeki, Takashi Taniguchi et al. · 2007 · FEBS Letters
  97. A highly insoluble state of Aβ similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice
    Ola Philipson, Per Hammarström, K. Peter R. Nilsson, Erik Portelius, Tommie Olofsson, Martin Ingelsson, Bradley T. Hyman, Kaj Blennow, Lars Lannfelt, Hannu Kalimo et al. · 2008 · Neurobiology of Aging
  98. The Essential Role of Soluble Aβ Oligomers in Alzheimer’s Disease
    Wang, Zi-Xuan, Tan, Lan, Liu, Jinyuan, Yu, Jin-Tai · 2016 · Molecular Neurobiology
  99. Brain Shuttle Antibody for Alzheimer’s Disease with Attenuated Peripheral Effector Function due to an Inverted Binding Mode
    Felix C. Weber, Bernd Bohrmann, Jens Niewoehner, Jens A. A. Fischer, Petra Rueger, Georg Tiefenthaler, Joerg Moelleken, Alexander Bujotzek, Kevin Brady, Thomas Singer et al. · 2018 · Cell Reports
  100. Antibody-Mediated Phagocytosis of the Amyloid β-Peptide in Microglia Is Differentially Modulated by C1q
    Scott D. Webster, Manuel D Galvan, Erick Ferran, William Garzon-Rodriguez, Charles G. Glabe, Andrea J. Tenner · 2001 · The Journal of Immunology